Non-small-cell lung cancer: how to manage EGFR-mutated disease
Federica Pecci, Luca Cantini, Giulio Metro, Biagio Ricciuti, Giuseppe Lamberti, Ammad Ahmad Farooqı, Rossana Berardi
Abstract
-mutant advanced non-small-cell lung cancer, discussing the biological rationale underlying the development of a forefront combination of TKI and/or new antibody-drug conjugates. We also suggest a treatment algorithm that could be followed considering the latest published data.
Topics & Concepts
OsimertinibMedicineLung cancerEpidermal growth factor receptorCancer researchTyrosine kinaseTargeted therapyDrug resistanceAcquired resistanceCancerBioinformaticsOncologyComputational biologyErlotinibInternal medicineBiologyReceptorGeneticsLung Cancer Treatments and MutationsLung Cancer Diagnosis and TreatmentLung Cancer Research Studies